BEAT earnings analysis
What we found in BEAT's 10-Q: the parts that mattered, the offsets in the same document, and what the company said about what comes next.
Our reading of the filing · Free to read, no account needed
The provided 10-Q extract does not include the income statement, balance sheet, cash-flow statement, MD&A, or segment disclosures, so revenue, margins, EPS, cash flow, liquidity, and year-over-year trends cannot be assessed. The filing does report effective disclosure controls as of June 30, 2026, no material control changes during the quarter, no material legal proceedings, and no derivatives or hedging activities. No quantitative guidance or risk-factor updates were provided.
The parts that mattered.
Pulled out of the filing itself, with the figures the company reported.
- Disclosure controls deemed effective
- Management concluded that disclosure controls and procedures were effective as of June 30, 2026, providing reasonable assurance that required information is reported within SEC timelines.
- No material control changes
- The company reported no changes in internal control over financial reporting during the fiscal quarter ended June 30, 2026 that materially affected, or were reasonably likely to materially affect, those controls.
- No derivatives or hedging exposure
- The company stated that it does not hold derivative instruments and does not engage in hedging activities; quantitative and qualitative market-risk disclosures were not required because it is a smaller reporting company.
- No material legal proceedings
- Management stated that no legal actions, suits, proceedings, inquiries, or investigations were pending or threatened in which an adverse decision could have a material adverse effect.
And the other side of it.
The offsets in the same document — the things a summary that only listed the good news would have left out.
- No updated risk-factor disclosure
- Risk Factor disclosure was marked “Not applicable” under Item 1A because HeartBeam qualifies as a smaller reporting company. Accordingly, the filing provides no updated risk-factor detail versus the prior report.
- No hedging protection
- The company stated it does not hold derivative instruments or engage in hedging activities under Item 3; therefore, it has no reported hedge protection against market-risk exposures.
What they said about what is next.
The provided 10-Q text contains no quantitative revenue or EPS outlook. Outlook and guidance were not provided in the filing.
The filing reads about the same as the one before it.
What came before.
- 10-Q · May 13, 2026
- HeartBeam reported a Q1 2026 net loss of $4.7 million, which reflects a 14% improvement from a loss of $5.5 million in Q1 2025. Operating expenses decreased by 14% to $4.716 million, driven by a reduction in R&D costs,…
- 10-Q · November 13, 2025
- HeartBeam reported a Q3 net loss of $5.255 million (EPS $(0.15)), slightly wider sequentially vs Q2 but improved versus prior-year quarter EPS ($(0.19)). Operating expenses rose to $5.29 million driven by higher R&D;…
- 10-Q · August 14, 2024
- HeartBeam reported a wider Q2 net loss of $4,956,000 (EPS -$0.19) versus $3,154,000 (EPS -$0.16) in Q2 2023, driven by higher operating expenses (Q2 operating expense $5,090,000 vs $3,312,000). Cash declined to…
- 10-Q · May 9, 2024
- HeartBeam reported a net loss of $4,606,000 for the three months ended March 31, 2024, versus a $4,136,000 loss a year earlier; diluted loss per share improved to $(0.17) from $(0.50) due to a higher weighted average…
This is our reading of a public filing, not the filing. Read the original on SEC.gov · Educational only. Nothing here is investment advice.
Read the next one first.
We read every filing BEAT makes the day it lands, and put it next to what the options market did about it. Members get both, and an alert when a filing arrives.
Cancel anytime · Month to month · Switch tiers whenever